An Update on Local Steroids for Uveitis - Summary - MDSpire

An Update on Local Steroids for Uveitis

  • By

  • Sruthi Arepalli, MD

  • July 14, 2025

  • 4 min

Share

Objective:

To review recent developments in the US market for locally delivered steroid therapies for uveitis, including product discontinuations, relaunches, and label expansions, and their clinical implications.

Key Findings:
  • Retisert will be discontinued in April 2026 due to manufacturing issues, impacting patients reliant on this treatment.
  • Triesence has been relaunched with a significant price increase after a prolonged shortage, raising concerns about patient access.
  • Yutiq and Iluvien have expanded indications for chronic noninfectious uveitis, providing alternative options for patients.
Interpretation:

The changes in the availability of local steroid therapies for uveitis necessitate careful consideration of alternative treatments, such as Yutiq and Iluvien, for patients affected by these discontinuations.

Limitations:
  • The article does not provide data on patient outcomes following the transition to alternative therapies, which is crucial for assessing treatment efficacy.
  • Potential impacts of increased costs on patient access to treatment are not discussed, which could affect treatment adherence.
Conclusion:

The landscape of local steroid treatments for uveitis is evolving, with significant implications for patient management and treatment options, necessitating a reassessment of therapeutic strategies.

Original Source(s)

An Update on Local Steroids for Uveitis

  • by Sruthi Arepalli, MD

  • July 14, 2025

Related Content

Targeting IL-6 in the Treatment of Uveitic Macular Edema

Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

Clinical Trial Update May/June 2026

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

  • May 1, 2026

  • 44 min